Moderated Poster

Poster, Podium & Video Sessions

MP40-19: Mirabegron in women with OAB: a real setting study

Saturday, May 13
3:30 PM - 5:30 PM
Location: BCEC: Room 153

Presentation Authors: Ester Illiano*, Perugia, Italy, Raffaele Balsamo, Catanzaro, Italy, Martina Milanesi, Vincenzo Li Marzi, Florence, Italy, Enrico Finazzi Agrò, Franca Natale, Rome, Italy, Stefania Maddonni, Elisabetta Costantini, Perugia, Italy

Introduction: The aims of this study were to evaluate the medication adherence, the patient’s satisfaction and the improvement of symptoms and
of quality of life in women with OAB after treatment with Mirabegron.

Methods: This is an multicenter prospective study.Consecutive female patients affected by OAB were enrolled. Inclusion criteria were: women with OAB naïve, women with refractory OAB to antimuscarinic drugs. Exclusion criteria were:hypertension, renal and hepatic impairment, QT prolongation. Pre-treatment evaluation: microbiological analysis, abdominal ultrasonography, uroflowmetry (UF) with post-void residual (PVR) measurement and voiding diary (VD). They completed OABq- sf questionnaire. They received once-daily Mirabegron 50 mg for 6 months.They were followed up at 1,3,6 months post treatment with UF and PVR measurement and 3-days VD, OABq-sf, MMAS-4 sf, sVAS and PGI-I questionnaries. Statistical analysis : McNemar and Friedman tests, p-value <0.05

Results: Ninety-two women (mean age of 56.4±13.4 years) were included in the study. 23 and 33 patients interrupted the treatment at 1 and 3 months respectively. Graph I (A,B) showed the discontinuation reasons. 36 out of 92 women were evaluated at 6 months with a high drug adherence (median MMAS-4 score of 0 (range 0-2) ). At 6 months follow-up patient’s satisfaction was high, infact median PGI-I and S-VAS were 2 (range 1-4) and 8 (2-10) respectively. At 1,3,6 months OABq-sf score showed a statistically significant improvement with a baseline median score of 36 (range 19-99), of 9 (range 7-24) at 6 months (p=0.001). Graph 1C showed an improvement of all the OAB symptoms at 1 and 3 months, but they were stable at 6 months. Furthermore a statistically significant decrement of the mean number of pads/die was evident at 6 month (1.45±1.58 vs 0.57 ± 0.98 p<0.0001).UF results showed no statistical changes at 1 month and at 6 months.The results are not different in women with OAB naïve and women with OAB refractory to antimuscarinic drugs

Conclusions: Mirabegron 50mg showed significant subjective and objective efficacy with a high in women with OAB at 1 and 3 months of treatment. For the low side-effects and its impact on QoL, it can be considered the first line therapy in these patients. Long term results are mandatory for patients perspective and counselling for tailored therapy.

Source Of Funding: none

Send Email for Ester Illiano


MP40-19: Mirabegron in women with OAB: a real setting study

Attendees who have favorited this

Send Email for Mirabegron in women with OAB: a real setting study